SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (740)9/27/2005 11:41:49 AM
From: former_pgs  Respond to of 946
 
To add to that, women with lung cancer seem to do a little better, and may also have better responses to therapy. In Tarceva's trial, women on Tarceva clearly had higher response rates than men, and the median survival numbers for women on placebo and women on tarceva were greater than the comparable men's group.



To: Icebrg who wrote (740)9/27/2005 11:42:53 AM
From: Extra Pale  Read Replies (1) | Respond to of 946
 
wonder why gender difference has not surfaced before in prior taxane drug studies? or perhaps it has?

anyway, I had bought some bottom fishing with pix results in mind, today is a definite bonus.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News